{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:27Z","timestamp":1793155827131,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40257-024-00876-x","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T11:02:04Z","timestamp":1719918124000},"page":"837-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial"],"prefix":"10.1007","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct04061252","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-5096","authenticated-orcid":false,"given":"Masamoto","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-0216","authenticated-orcid":false,"given":"Shigetoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1411-8299","authenticated-orcid":false,"given":"Yoshiumi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-4311","authenticated-orcid":false,"given":"Tadashi","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"876_CR1","first-page":"CD011628","volume":"1","author":"G Obeid","year":"2020","unstructured":"Obeid G, Do G, Kirby L, Hughes C, Sbidian E, Le Cleach L. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. 2020;1:CD011628.","journal-title":"Cochrane Database Syst Rev"},{"key":"876_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/bjd.12223","volume":"168","author":"AMG Brunasso","year":"2013","unstructured":"Brunasso AMG, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013;168:1243\u201351.","journal-title":"Br J Dermatol"},{"key":"876_CR3","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.5070\/D3234034627","volume":"23","author":"D Wilsmann-Theis","year":"2017","unstructured":"Wilsmann-Theis D, Jacobi A, Frambach Y, Philipp S, Weyergraf A, Schill T, et al. Palmoplantar pustulosis - a cross-sectional analysis in Germany. Dermatol Online J. 2017;23:13030.","journal-title":"Dermatol Online J"},{"key":"876_CR4","doi-asserted-by":"publisher","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5:e006450\u2013e006450.","journal-title":"BMJ Open"},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09546631003636817","volume":"22","author":"AC de Waal","year":"2011","unstructured":"de Waal AC, van de Kerkhof PCM. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatol Treat. 2011;22:102\u20135.","journal-title":"J Dermatol Treat"},{"key":"876_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bjd.20087","volume":"185","author":"S L\u00f6fvendahl","year":"2021","unstructured":"L\u00f6fvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study*. Br J Dermatol. 2021;185:945\u201351.","journal-title":"Br J Dermatol"},{"key":"876_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","volume":"98","author":"M Murakami","year":"2020","unstructured":"Murakami M, Terui T. Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98:13\u20139.","journal-title":"J Dermatol Sci"},{"key":"876_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1365-2133.1930.tb09380.x","volume":"42","author":"HW Barber","year":"1930","unstructured":"Barber HW. Acrodermatitis continua vel perstans (Dermatitis repens) and Psoriasis pustulosa. Br J Dermatol. 1930;42:500\u201318.","journal-title":"Br J Dermatol"},{"key":"876_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2133.2006.07675.x","volume":"156","author":"CEM Griffiths","year":"2007","unstructured":"Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156:258\u201362.","journal-title":"Br J Dermatol"},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/archderm.1935.01470060002001","volume":"32","author":"GC Andrews","year":"1935","unstructured":"Andrews GC. Pustular bacterids of the hands and feet. Arch Dermatol. 1935;32:837.","journal-title":"Arch Dermatol"},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1046\/j.1523-1747.2003.12094.x","volume":"120","author":"K Asumalahti","year":"2003","unstructured":"Asumalahti K, Ameen M, Suomela S, Hagforsen E, Micha\u00eblsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627\u201332.","journal-title":"J Invest Dermatol"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamadermatol.2020.3275","volume":"156","author":"N Benzian-Olsson","year":"2020","unstructured":"Benzian-Olsson N, Dand N, Chaloner C, Bata-Csorgo Z, Borroni R, Burden AD, et al. Association of clinical and demographic factors with the severity of palmoplantar pustulosis. JAMA Dermatol. 2020;156:1216\u201322.","journal-title":"JAMA Dermatol"},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.abd.2019.04.008","volume":"95","author":"A Oktem","year":"2020","unstructured":"Oktem A, Uysal PI, Akdo\u011fan N, Tokmak A, Yalcin B. Clinical characteristics and associations of palmoplantar pustulosis: an observational study. An Bras Dermatol. 2020;95:15\u20139.","journal-title":"An Bras Dermatol"},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ced.14829","volume":"47","author":"S Sar\u0131kaya Solak","year":"2022","unstructured":"Sar\u0131kaya Solak S, Kara Polat A, Kilic S, Oguz Topal I, Saricaoglu H, Karadag AS, et al. Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross-sectional, multicentre study of 263 patients. Clin Exp Dermatol. 2022;47:63\u201371.","journal-title":"Clin Exp Dermatol"},{"key":"876_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/CCID.S240607","volume":"13","author":"E Freitas","year":"2020","unstructured":"Freitas E, Rodrigues MA, Torres T. Diagnosis, screening and treatment of patients with palmoplantar pustulosis (PPP): a review of current practices and recommendations. Clin Cosmet Investig Dermatol. 2020;13:561\u201378.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"876_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.2011.10233.x","volume":"164","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, van de Kerkhof PCM. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol. 2011;164:942\u20136.","journal-title":"Br J Dermatol"},{"key":"876_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232738","volume":"15","author":"C Miyazaki","year":"2020","unstructured":"Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study. PLoS ONE. 2020;15: e0232738.","journal-title":"PLoS ONE"},{"key":"876_CR18","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","volume":"155","author":"T Terui","year":"2019","unstructured":"Terui T, Kobayashi S, Okubo Y, Murakami M, Zheng R, Morishima H, et al. Efficacy and safety of guselkumab in Japanese patients With palmoplantar pustulosis: A phase 3 randomized clinical trial. JAMA Dermatol. 2019;155:1153\u201361.","journal-title":"JAMA Dermatol"},{"key":"876_CR19","first-page":"1387","volume":"21","author":"N Rahbar Kooybaran","year":"2023","unstructured":"Rahbar Kooybaran N, Tsianakas A, Assaf K, Mohr J, Wilsmann-Theis D, M\u00f6ssner R. Response of palmoplantar pustulosis to upadacitinib: A case series of five patients. J Dtsch Dermatol Ges. 2023;21:1387\u201392.","journal-title":"J Dtsch Dermatol Ges"},{"key":"876_CR20","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1111\/ajd.13117","volume":"61","author":"D Haynes","year":"2020","unstructured":"Haynes D, Topham C, Hagstrom E, Greiling T. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: a case report. Australas J Dermatol. 2020;61:e108\u201310.","journal-title":"Australas J Dermatol"},{"key":"876_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clim.2016.10.003","volume":"173","author":"T Koga","year":"2016","unstructured":"Koga T, Sato T, Umeda M, Fukui S, Horai Y, Kawashiri S-Y, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation. Clin Immunol. 2016;173:147\u20138.","journal-title":"Clin Immunol"},{"key":"876_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13753","volume":"33","author":"R M\u00f6ssner","year":"2020","unstructured":"M\u00f6ssner R, Hoff P, Mohr J, Wilsmann-Theis D. Successful therapy of palmoplantar pustulosis with tofacitinib-Report on three cases. Dermatol Ther. 2020;33: e13753.","journal-title":"Dermatol Ther"},{"key":"876_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jdcr.2019.12.006","volume":"6","author":"YA Wang","year":"2020","unstructured":"Wang YA, Rosenbach M. Successful treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis with tofacitinib: Report of case. JAAD Case Rep. 2020;6:115\u20138.","journal-title":"JAAD Case Rep."},{"key":"876_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","volume":"17","author":"Y Pang","year":"2024","unstructured":"Pang Y, D\u2019Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K. Risankizumab: Mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17: e13706.","journal-title":"Clin Transl Sci"},{"key":"876_CR25","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/1346-8138.16132","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Morishima H, Zheng R, Terui T. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study. J Dermatol. 2021;48:1838\u201353.","journal-title":"J Dermatol"},{"key":"876_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jdv.12272","volume":"28","author":"R Bissonnette","year":"2014","unstructured":"Bissonnette R, Nigen S, Langley RG, Lynde CW, Tan J, Fuentes-Duculan J, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28:1298\u2013305.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"876_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1600-0625.2010.01224.x","volume":"20","author":"K Torii","year":"2011","unstructured":"Torii K, Saito C, Furuhashi T, Nishioka A, Shintani Y, Kawashima K, et al. Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients. Exp Dermatol. 2011;20:371\u20133.","journal-title":"Exp Dermatol"},{"key":"876_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1600-0625.2011.01325.x","volume":"20","author":"M Murakami","year":"2011","unstructured":"Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845\u20137.","journal-title":"Exp Dermatol"},{"key":"876_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1365-2133.2010.09819.x","volume":"163","author":"E Hagforsen","year":"2010","unstructured":"Hagforsen E, Hedstrand H, Nyberg F, Micha\u00eblsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol. 2010;163:572\u20139.","journal-title":"Br J Dermatol"},{"key":"876_CR30","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/jdv.12203","volume":"27","author":"DY Kim","year":"2013","unstructured":"Kim DY, Kim JY, Kim TG, Kwon JE, Sohn H, Park J, et al. A comparison of inflammatory mediator expression between palmoplantar pustulosis and pompholyx. J Eur Acad Dermatol Venereol. 2013;27:1559\u201365.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"876_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamadermatol.2023.5051","volume":"160","author":"T Passeron","year":"2024","unstructured":"Passeron T, Perrot J-L, Jullien D, Goujon C, Ruer M, Boy\u00e9 T, et al. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab. JAMA Dermatol. 2024;160:199.","journal-title":"JAMA Dermatol"},{"key":"876_CR32","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s40265-016-0634-8","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL. Brodalumab: First Global Approval. Drugs. 2016;76:1403\u201312.","journal-title":"Drugs"},{"key":"876_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s13555-022-00746-6","volume":"12","author":"A Menter","year":"2022","unstructured":"Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. Dermatol Ther (Heidelb). 2022;12:1289\u2013302.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"876_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/1346-8138.14815","volume":"46","author":"A Pinter","year":"2019","unstructured":"Pinter A, Wilsmann-Theis D, Peitsch WK, M\u00f6ssner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol. 2019;46:426\u201330.","journal-title":"J Dermatol"},{"key":"876_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1684\/ejd.2018.3325","volume":"28","author":"M Nakao","year":"2018","unstructured":"Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 2018;28:538\u20139.","journal-title":"Eur J Dermatol"},{"key":"876_CR36","unstructured":"WMA The World Medical Association. WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 16 Jan 2024"},{"key":"876_CR37","unstructured":"Council for International Organizations of Medical Sciences. International ethical guidelines for health-related research involving humans. Available from: https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf. Accessed 16 Jan 2024"},{"key":"876_CR38","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Official web site\u202f: ICH. Ich."},{"key":"876_CR39","doi-asserted-by":"crossref","unstructured":"Fukasawa T, Yamashita T, Enomoto A, Yoshizaki-Ogawa A, Miyagawa K, Sato S, et al. Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta-analysis-based comparison of treatment efficacy. J Eur Acad Dermatol Venereol. 2024;38:281\u20138.","DOI":"10.1111\/jdv.19499"},{"key":"876_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, et al. The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11: 594735.","journal-title":"Front Immunol"},{"key":"876_CR41","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/jid.2010.87","volume":"130","author":"M Murakami","year":"2010","unstructured":"Murakami M, Ohtake T, Horibe Y, Ishida-Yamamoto A, Morhenn VB, Gallo RL, et al. Acrosyringium is the main site of the vesicle\/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010;130:2010\u20136.","journal-title":"J Invest Dermatol"},{"key":"876_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110677","volume":"9","author":"M Murakami","year":"2014","unstructured":"Murakami M, Kaneko T, Nakatsuji T, Kameda K, Okazaki H, Dai X, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS ONE. 2014;9: e110677.","journal-title":"PLoS One"},{"key":"876_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.13846","volume":"31","author":"M Misiak-Galazka","year":"2016","unstructured":"Misiak-Galazka M, Wolska H, Rudnicka L. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2016;31:38\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"876_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273\u201386.","journal-title":"Br J Dermatol"},{"key":"876_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81:44\u201352.","journal-title":"J Dermatol Sci"},{"key":"876_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/pathogens8020054","volume":"8","author":"F Sparber","year":"2019","unstructured":"Sparber F, LeibundGut-Landmann S. Interleukin-17 in antifungal immunity. Pathogens. 2019;8:54.","journal-title":"Pathogens"},{"key":"876_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4049\/jimmunol.1602185","volume":"199","author":"A Floudas","year":"2017","unstructured":"Floudas A, Saunders SP, Moran T, Schwartz C, Hams E, Fitzgerald DC, et al. IL-17 receptor A aaintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol. 2017;199:707\u201317.","journal-title":"J Immunol"},{"key":"876_CR48","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/1346-8138.15826","volume":"48","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J Dermatol. 2021;48:750\u201360.","journal-title":"J Dermatol"},{"key":"876_CR49","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1346-8138.1995.tb03948.x","volume":"22","author":"T Akiyama","year":"1995","unstructured":"Akiyama T, Seishima M, Watanabe H, Nakatani A, Mori S, Kitajima Y. The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol. 1995;22:930\u20134.","journal-title":"J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00876-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T07:26:14Z","timestamp":1728977174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00876-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"10 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Kyowa Kirin Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y\u00a0Okubo reports grants from Kyowa Kirin during the conduct of the study and grants and\/or personal fees from AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Shiseido, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma outside the submitted work. SK reports grants from Kyowa Kirin during the conduct of the study and personal fees from AbbVie, Janssen Pharma, and Taiho Pharmaceutical outside the submitted work. MM reports grants from Kyowa Kirin during the conduct of the study and grants and\/or personal fees from AbbVie, Amgen Inc., Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, Kyowa Kirin, Maruho, Novartis Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical outside the submitted work. SS reports grants from Kyowa Kirin during the conduct of the study and grants and\/or personal fees from AbbVie, Amgen Inc., Eisai, Eli Lilly, Janssen Pharma, Kaken Pharmaceutical, Kyowa Kirin, Maruho, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Zoki Pharmaceutical, Sanofi, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma outside the submitted work. NK is an employee of Kyowa Kirin. Y Ouchi is an employee of Kyowa Kirin. TT reports personal fees from Kyowa Kirin during the conduct of the study and grants and\/or personal fees from AbbVie, Amgen Inc., Boehringer Ingelheim, Maruho, and Taiho Pharmaceutical outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study (NCT04061252) was conducted in compliance with the protocol, the Declaration of Helsinki (World Medical Association [WMA]), the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice Guidelines, and other applicable laws and regulations. It was approved by the concerned institutional review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval:"}},{"value":"All participants gave written informed consent to participate in the research and publish the results.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Publish"}},{"value":"The data that support the findings of this study will be available in the Vivli repository () as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied. Individual participant data (text, tables, figures, and appendices) that provide the basis for the results reported in this paper will be deidentified and shared.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article. Conceptualization: All authors contributed equally. Investigation: All authors contributed equally. Data curation: NK and Y Ouchi. Formal analysis: Y Ouchi. Methodology: NK and Y Ouchi. Writing: All authors contributed equally. Review\/editing: All authors contributed equally. All authors have given their approval for this version to be published and are in agreement to be accountable for all aspects of the work as a whole.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}